A One-Dose Wonder Against Recurring Malaria

A drug targeting recurring malaria crossed another hurdle, winning approval from the FDA (which did, however, underscore important side effects).
Tafenoquine can flush the malaria-causing plasmodium vivax parasite out of the liver, where it hides and reawakens. Relapsing malaria, the most common form outside sub-Saharan Africa, sickens 8.5 million people annually.
"The ability to get rid of the parasite in the liver with a single dose of tafenoquine is a phenomenal achievement and in my mind it represents one of the most significant advances in malaria treatment in the last 60 years,” said Oxford University’s Ric Price. Next, regulators in countries dogged by this form of malaria will need to assess this drug.


Secondary Topic
Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top